Corymbiferin, a chemical compound, exhibits significant anti-diabetic properties by enhancing antioxidant capacity and carbohydrate metabolism in diabetic rodents. In addition, Corymbiferin promotes the improvement of histopathology in both the liver and pancreatic β cells.

Administering Corymbiferin to male Wistar rats at a dosage of 40 mg/kg orally significantly lowers the fasting blood glucose (FBG) level, closely mirroring the beneficial impact observed with metformin in diabetic rats[1]. Furthermore, a higher dose of Corymbiferin (400 mg/kg; orally) markedly decreases the blood glucose level and demonstrates an efficacy akin to that of metformin in the oral glucose tolerance test (OGTT)[1].